Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib
Abstract Objective Anti‐MDA5 antibody‐positive dermatomyositis (DM) is a rare clinical autoimmune disease, and anti‐MDA5‐positive DM with interstitial lung disease (ILD) is the most important cause of death in DM patients. We reported the efficacy of the JAK1/3 inhibitor tofacitinib as an anti‐MDA5‐...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2023-06-01
|
| Col·lecció: | Immunity, Inflammation and Disease |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/iid3.897 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|